Our results demonstrate that increased expression of Class IIa HDACs, in particular HDAC4 and -9, occurs in basal BC cell lines and invasive clinical specimens suggesting this class of HDACs may be best suited for targeted inhibition in patients with basal BC. Here, HDAC4 is linked to breast cancer.